Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 6/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8966365 | 0.88 | PIK3CA (0.41) | PIK3CACSNK1DKDRRIPK1MAOB | |
| SCHEMBL8965644 | 0.87 | PIK3CA (0.42) | PIK3CACSNK1DKDRRIPK1 | |
| SCHEMBL8965590 | 0.87 | PIK3CA (0.45) | PIK3CACSNK1DKDRRIPK1MAOB | |
| SCHEMBL8965525 | 0.86 | PIK3CA (0.41) | PIK3CACSNK1DKDRRIPK1MAOB | |
| SCHEMBL8965972 | 0.86 | PIK3CA (0.46) | PIK3CACSNK1DKDRRIPK1MAOB | |
| SCHEMBL8965601 | 0.84 | RIPK1 (0.42) | PIK3CACSNK1DKDRRIPK1CSNK1E | |
| SCHEMBL8965653 | 0.84 | KDR (0.41) | PIK3CACSNK1DKDR | |
| SCHEMBL8966177 | 0.83 | PIK3CA (0.40) | PIK3CACSNK1DKDRRIPK1MAOB | |
| SCHEMBL8965523 | 0.83 | PIK3CA (0.47) | PIK3CACSNK1DKDRRIPK1CSNK1E | |
| SCHEMBL8965909 | 0.83 | PIK3CA (0.42) | PIK3CAKDRRIPK1MAOBPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5538970-A | Treatment of cancer with imidazo-1,2-pyridazin compounds | GLAXO WELLCOME INC. (US) | 1996-07-23 | — | — | US | disclosed |
| US-5447956-A | Anticarcinogenic agents | BURROUGHS WELLCOME CO. (US) | 1995-09-05 | — | — | US | disclosed |
| US-5380759-A | Methyl N-[6-(3,4,5-trimethoxybenzloxy)imidazo[1,2-b]pyridazin-2-zyl]carbamate used to treat leukemia | BURROUGHS WELLCOME CO. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5371219-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0305093-B1 | Imidazo(1,2-b)pyridazine derivatives | WELLCOME FOUND (GB) | 1994-04-06 | — | — | EP | disclosed |
| US-5091531-A | Antitumor agents | BURROUGHS WELLCOME CO. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0305093-A1 | Imidazo(1,2-b)pyridazine derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-03-01 | — | — | EP | disclosed |